Klebsiella pneumoniae Infections R&D Pipeline Analysis Report, Q4 2020
Klebsiella pneumoniae Infections Pipeline Overview
The Q4 Klebsiella pneumoniae Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Klebsiella pneumoniae Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Klebsiella pneumoniae Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Klebsiella pneumoniae Infections disease overview, Klebsiella pneumoniae Infections types, Klebsiella pneumoniae Infections symptoms, causes, and FDA/EMA approved treatment options.
Klebsiella pneumoniae Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Klebsiella pneumoniae Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Klebsiella pneumoniae Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 32 companies. Business profiles and contact details of the companies actively perusing Klebsiella pneumoniae Infections pipeline are assessed.
Klebsiella pneumoniae Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Klebsiella pneumoniae Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Klebsiella pneumoniae Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Klebsiella pneumoniae Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Klebsiella pneumoniae Infections Pipeline Market News and Developments during 2020
The Klebsiella pneumoniae Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Klebsiella pneumoniae Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Klebsiella pneumoniae Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Klebsiella pneumoniae Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Klebsiella pneumoniae Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Klebsiella pneumoniae Infections disease overview, Klebsiella pneumoniae Infections types, Klebsiella pneumoniae Infections symptoms, causes, and FDA/EMA approved treatment options.
Klebsiella pneumoniae Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Klebsiella pneumoniae Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Klebsiella pneumoniae Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 32 companies. Business profiles and contact details of the companies actively perusing Klebsiella pneumoniae Infections pipeline are assessed.
Klebsiella pneumoniae Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Klebsiella pneumoniae Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Klebsiella pneumoniae Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Klebsiella pneumoniae Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Klebsiella pneumoniae Infections Pipeline Market News and Developments during 2020
The Klebsiella pneumoniae Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Klebsiella pneumoniae Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Klebsiella pneumoniae Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 32 companies are included including ABAC Therapeutics SA, AEON Medix Inc, Affinivax Inc, Akthelia Pharmaceuticals Ltd, Appili Therapeutics Inc, Armata Pharmaceuticals Inc, BB200 LLC, Bugworks Research India Pvt Ltd, Celdara Medical LLC, ContraFect Corp, Debiopharm International SA, EnBiotix Inc, F. Hoffmann-La Roche Ltd, Fedora Pharmaceuticals Inc, Forge Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Melinta Therapeutics Inc, Microbiotix Inc, Neoculi Pty Ltd, Nosopharm SAS, Oryn Therapeutics, Peptilogics Inc, Phico Therapeutics Ltd, ReAlta Life Sciences Inc, REMAb Therapeutics SL, Shionogi & Co Ltd, Soligenix Inc, Spero Therapeutics Inc, Summit Therapeutics Plc, Syntiron LLC, VaxNewMO LLC, Vaxxilon AG,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Klebsiella pneumoniae Infections pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Klebsiella pneumoniae Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Klebsiella pneumoniae Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Klebsiella pneumoniae Infections pipeline
2.5 Active Companies Developing Klebsiella pneumoniae Infections pipeline
3. KLEBSIELLA PNEUMONIAE INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 ABAC Therapeutics SA
AEON Medix Inc
Affinivax Inc
Akthelia Pharmaceuticals Ltd
Appili Therapeutics Inc
Armata Pharmaceuticals Inc
BB200 LLC
Bugworks Research India Pvt Ltd
Celdara Medical LLC
ContraFect Corp
Debiopharm International SA
EnBiotix Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Microbiotix Inc
Neoculi Pty Ltd
Nosopharm SAS
Oryn Therapeutics
Peptilogics Inc
Phico Therapeutics Ltd
ReAlta Life Sciences Inc
REMAb Therapeutics SL
Shionogi & Co Ltd
Soligenix Inc
Spero Therapeutics Inc
Summit Therapeutics Plc
Syntiron LLC
VaxNewMO LLC
Vaxxilon AG
5. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Klebsiella pneumoniae Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Klebsiella pneumoniae Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Klebsiella pneumoniae Infections pipeline
2.5 Active Companies Developing Klebsiella pneumoniae Infections pipeline
3. KLEBSIELLA PNEUMONIAE INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 ABAC Therapeutics SA
AEON Medix Inc
Affinivax Inc
Akthelia Pharmaceuticals Ltd
Appili Therapeutics Inc
Armata Pharmaceuticals Inc
BB200 LLC
Bugworks Research India Pvt Ltd
Celdara Medical LLC
ContraFect Corp
Debiopharm International SA
EnBiotix Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Microbiotix Inc
Neoculi Pty Ltd
Nosopharm SAS
Oryn Therapeutics
Peptilogics Inc
Phico Therapeutics Ltd
ReAlta Life Sciences Inc
REMAb Therapeutics SL
Shionogi & Co Ltd
Soligenix Inc
Spero Therapeutics Inc
Summit Therapeutics Plc
Syntiron LLC
VaxNewMO LLC
Vaxxilon AG
5. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. KLEBSIELLA PNEUMONIAE INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
